Bleeding Behind the Eye: Diagnosis and Management in Anticoagulated Patients
Immediate Diagnostic Approach
Bleeding behind the eye in a patient on anticoagulants requires urgent ophthalmologic evaluation to distinguish between vision-threatening hemorrhages (vitreous, subretinal, retrobulbar, or intraocular) versus less critical bleeding, as the location determines both prognosis and anticoagulation management. 1, 2
Critical Diagnostic Elements
- Perform dilated fundoscopic examination with indirect ophthalmoscopy and scleral depression to identify the specific bleeding location: vitreous hemorrhage, subretinal hemorrhage, retrobulbar hemorrhage, or intraocular bleeding 1
- Assess visual acuity immediately, as monocular vision changes or blindness indicate intraocular hemorrhage requiring emergent intervention 2
- Check for proptosis, severe eye pain, and ophthalmoplegia, which suggest retrobulbar hemorrhage with potential for central retinal artery occlusion and permanent vision loss 3
- Obtain B-scan ultrasonography if media opacity prevents adequate fundoscopic examination to search for retinal tears, retinal detachment, or mass lesions causing the hemorrhage 1
Laboratory Assessment
- Measure INR immediately in warfarin patients to determine degree of anticoagulation and guide reversal decisions 4
- Document hemoglobin and assess for hemodynamic instability (systolic BP <90 mmHg, heart rate elevation, orthostatic changes) to classify bleeding severity 2
Classification of Bleeding Severity
Major (Vision-Threatening) Ocular Bleeding
Intraocular hemorrhage is classified as a critical site bleed with potential for permanent vision loss, requiring immediate anticoagulation reversal consideration 2:
- Retrobulbar hemorrhage: Can cause central retinal artery occlusion, optic nerve compression, and blindness within hours 3
- Massive subretinal hemorrhage: Associated with permanent vision loss, particularly in anticoagulated patients where bleeding is more extensive 5
- Dense vitreous hemorrhage obscuring all retinal details: Prevents assessment for underlying retinal tears and increases risk of retinal detachment 1
Non-Major Ocular Bleeding
- Mild-moderate vitreous hemorrhage with visible retina: Often clears spontaneously with observation 1
- Small subconjunctival hemorrhage: Benign, self-limited, requires no intervention 6
Anticoagulation Management Algorithm
For Major (Vision-Threatening) Ocular Bleeding
Immediately withhold warfarin and consider reversal therapy for any intraocular hemorrhage threatening vision 4, 7:
Warfarin Reversal Protocol
- For INR 2.0-5.0 with major ocular bleeding: Withhold warfarin and administer vitamin K 5-10 mg by slow IV infusion over 30 minutes 4, 7
- For INR >5.0 with major ocular bleeding: Administer four-factor prothrombin complex concentrate (4F-PCC) 25-50 units/kg based on INR level, plus vitamin K 5-10 mg IV 2, 8
- INR 2 to <4: 25 units/kg
- INR 4-6: 35 units/kg
- INR >6: 50 units/kg 2
- Target INR <1.5 for life-threatening intraocular bleeding to achieve hemostasis 8
Direct Oral Anticoagulant (DOAC) Reversal
- For apixaban or rivaroxaban: Administer andexanet alfa per dosing protocol, or 4F-PCC if andexanet unavailable 2
- For dabigatran: Administer idarucizumab 5g IV 2
For Non-Major Ocular Bleeding
Continue anticoagulation without interruption for minor ocular bleeding such as small vitreous hemorrhages or subconjunctival hemorrhages 2, 7:
- Withhold one dose of warfarin only if INR is supratherapeutic (>3.5), then resume at usual maintenance dose 7
- Do not routinely stop aspirin, as it has minimal effect on ocular bleeding risk 9
Special Considerations for Surgical Intervention
Vitreoretinal Surgery in Anticoagulated Patients
Warfarin can be safely continued for most vitreoretinal procedures if INR is in therapeutic range (2.0-3.0), as strabismus and vitreoretinal surgeons routinely operate on anticoagulated patients 6, 10:
- No increase in suprachoroidal hemorrhage or major complications was found in patients continuing warfarin (INR median 2.3) compared to controls 10
- Aspirin should not be stopped prior to vitreoretinal surgery, as it has little effect on surgical bleeding 9
- Consider withholding warfarin only if INR >3.0 or patient has additional bleeding risk factors (age >75, renal failure, concomitant antiplatelet drugs) 4, 9
Bridging Anticoagulation for High-Risk Patients
For patients with mechanical heart valves (especially mitral position) or recent thromboembolism requiring warfarin interruption, initiate therapeutic-dose heparin when INR falls below 2.0 4, 11:
- Start unfractionated heparin or LMWH 48 hours before surgery when warfarin is held 11
- Stop heparin 4-6 hours before procedure, restart as early as bleeding stability allows 11
- Continue heparin until INR is therapeutic for >48 hours after warfarin restart 11, 7
Common Clinical Scenarios
Vitreous Hemorrhage in Anticoagulated Patients
- Patients on warfarin with rhegmatogenous retinal detachment are 3 times more likely to present with vitreous hemorrhage compared to non-anticoagulated patients 10
- If vitreous hemorrhage obscures fundus examination, perform weekly B-scan ultrasonography until hemorrhage clears enough for indirect ophthalmoscopy with scleral depression 1
- Consider early vitrectomy (within 7 days) for dense vitreous hemorrhage to reduce risk of macula-involving retinal detachment 1
Recurrent Vitreous Hemorrhage
- Warfarin significantly increases risk of postoperative re-bleeding after diabetic vitrectomy (relative risk 6.185) 9
- For recurrent hemorrhage from retinal arterial macroaneurysm in anticoagulated patients, consider laser photocoagulation or endolaser during vitrectomy 12
Retrobulbar Hemorrhage
- This is a vision-threatening emergency requiring immediate intervention with lateral canthotomy/cantholysis if intraocular pressure is elevated 3
- Patients on both aspirin and warfarin have markedly increased risk of uncontrolled retrobulbar bleeding 3
Critical Pitfalls to Avoid
- Never withhold warfarin for minor ocular procedures (cataract surgery, glaucoma surgery) where bleeding is minimal and easily controlled 11
- Never use high-dose vitamin K (≥10 mg) for non-bleeding situations, as this creates warfarin resistance for up to one week 7
- Never abruptly discontinue warfarin in high-risk patients without bridging, as thrombosis markers increase with cessation 11, 7
- Do not confuse anticoagulant management with antiplatelet management—aspirin can generally be continued for ocular procedures 13, 9
- Do not delay ophthalmologic consultation for any patient with vision changes and ocular bleeding, as hours matter for retinal artery occlusion 2, 3
Restarting Anticoagulation
Resume warfarin at usual maintenance dose once adequate hemostasis is achieved and vision is stable 7:
- For non-major bleeding, restart within 24-48 hours after initial management 2
- For major bleeding requiring reversal, restart when bleeding risk has resolved (typically 7-14 days for intraocular hemorrhage) 2
- Recheck INR within 24-48 hours after restart and continue monitoring every 24-48 hours until stable in therapeutic range 7, 8